Analyzing the “One Big Beautiful Bill Act”: A Closer Look at its Impact on Prescription Drugs

The Trump administration’s new tax law, the “One Big Beautiful Bill Act” (OBBB), has stirred significant debate for its provisions addressing the cost of prescription drugs. While proponents argue the bill will foster innovation and lower drug costs, critics are concerned that it may ultimately benefit the pharmaceutical industry at the expense of patients and federal savings.

Key Provisions of the OBBB

The OBBB introduces several major changes that affect prescription drug policy:

Orphan Cures Act: This provision expands the exemption from Medicare price negotiation to include orphan drugs that treat multiple rare diseases, not just a single condition. This change is estimated to cost the government approximately $5 billion over 10 years.
Medicare Price Negotiation: The bill reverses key components of the Inflation Reduction Act of 2022 by expanding the list of drugs exempt from Medicare negotiation and delaying the implementation of new price controls. The Congressional Budget Office projects that this will result in a loss of about $5 billion in government savings over the next decade.
PBM Transparency in Medicaid: The OBBB includes measures to prohibit spread pricing in Medicaid-managed care and requires Pharmacy Benefit Managers (PBMs) to use a transparent pricing model. They must also report detailed cost and payment data to state and federal agencies upon request.
Tax Incentives: The bill extends and strengthens existing tax breaks for pharmaceutical companies, including research and development (R&D) credits and incentives for moving manufacturing back to the U.S. These incentives are bolstered by potential tariffs of up to 200% on imported drugs.

Benefits and Criticisms: A Mixed Bag

The OBBB presents a mixed picture, with both potential benefits and significant criticisms.

Benefits

Encourages Innovation: The expanded exemption for orphan drugs is seen by supporters as a way to restore incentives for pharmaceutical companies to develop multi-indication therapies for rare diseases.
Increased Transparency: The PBM reforms for Medicaid are expected to enhance financial oversight and could help save Medicaid dollars by eliminating opaque markups.
Favorable Industry Environment: The R&D tax advantages and tariff incentives are designed to encourage long-term investment and boost domestic drug production.

Criticisms

Higher Costs for Patients: Critics, including the AARP and patient advocacy groups, argue that by weakening Medicare’s negotiation power, the bill prioritizes “Big Pharma” profits over the needs of older adults, which could lead to higher out-of-pocket costs.
“Giveaway” to Pharma: The orphan cures exemption is criticized as a “multibillion-dollar giveaway” that undermines efforts to lower drug prices.
Threat to Patient Access: While PBM transparency is improved, the OBBB simultaneously proposes over $1 trillion in Medicaid funding cuts over a decade, along with new co-pays and eligibility requirements. Critics warn that these changes could threaten access to essential medications for low-income and rural patients.
Missed Opportunity: The final bill dropped proposals to extend PBM transparency reforms to Medicare Part D, a missed chance to bring systemic clarity to drug pricing across the broader healthcare system.

Conclusion

In its current form, the OBBB appears to benefit pharmaceutical companies through tax incentives and reduced price negotiation, while its impact on patients remains a point of contention. The bill may improve transparency in some areas, but its funding cuts to Medicaid and its weakened Medicare negotiation framework could potentially worsen affordability and access to care for vulnerable populations.